175 related articles for article (PubMed ID: 29702185)
1. COL5A1 may contribute the metastasis of lung adenocarcinoma.
Liu W; Wei H; Gao Z; Chen G; Liu Y; Gao X; Bai G; He S; Liu T; Xu W; Yang X; Jiao J; Xiao J
Gene; 2018 Jul; 665():57-66. PubMed ID: 29702185
[TBL] [Abstract][Full Text] [Related]
2. Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.
Volonte D; Vyas AR; Chen C; Dacic S; Stabile LP; Kurland BF; Abberbock SR; Burns TF; Herman JG; Di YP; Galbiati F
J Biol Chem; 2018 Feb; 293(5):1794-1809. PubMed ID: 29247004
[TBL] [Abstract][Full Text] [Related]
3. Detection of synchronous primary lung adenocarcinomas with genomic sequencing.
Berry D; Mahadevan M; Wick MR
Ann Diagn Pathol; 2018 Jun; 34():42-44. PubMed ID: 29661726
[TBL] [Abstract][Full Text] [Related]
4. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
Drosten M; Barbacid M
J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
[TBL] [Abstract][Full Text] [Related]
5. Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations.
Song DH; Lee B; Shin Y; Choi IH; Ha SY; Lee JJ; Hong ME; Choi YL; Han J; Um SW
Diagn Cytopathol; 2015 Jul; 43(7):539-44. PubMed ID: 25427298
[TBL] [Abstract][Full Text] [Related]
6. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
7. Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS-G12D mutation and P53 knockout.
Zhang M; Jiang N; Cui R; Du S; Ou H; Chen T; Ge R; Ma D; Zhang J
J Cell Mol Med; 2019 Oct; 23(10):6978-6988. PubMed ID: 31410985
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a human lung cancer cell line with high metastatic potential to multiple organs: gene expression associated with metastatic potential in human lung cancer.
Nakano T; Shimizu K; Kawashima O; Kamiyoshihara M; Kakegawa S; Sugano M; Ibe T; Nagashima T; Kaira K; Sunaga N; Ohtaki Y; Atsumi J; Takeyoshi I
Oncol Rep; 2012 Nov; 28(5):1727-35. PubMed ID: 22922681
[TBL] [Abstract][Full Text] [Related]
9. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
Kasinski AL; Slack FJ
Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
11. Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis.
Chuang CH; Greenside PG; Rogers ZN; Brady JJ; Yang D; Ma RK; Caswell DR; Chiou SH; Winters AF; Grüner BM; Ramaswami G; Spencley AL; Kopecky KE; Sayles LC; Sweet-Cordero EA; Li JB; Kundaje A; Winslow MM
Nat Med; 2017 Mar; 23(3):291-300. PubMed ID: 28191885
[TBL] [Abstract][Full Text] [Related]
12. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
13. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
14.
Lee YS; Lee JY; Song SH; Kim DM; Lee JW; Chi XZ; Ito Y; Bae SC
Mol Cells; 2020 Oct; 43(10):889-897. PubMed ID: 33115981
[No Abstract] [Full Text] [Related]
15. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma.
Gibbons DL; Lin W; Creighton CJ; Zheng S; Berel D; Yang Y; Raso MG; Liu DD; Wistuba II; Lozano G; Kurie JM
PLoS One; 2009; 4(4):e5401. PubMed ID: 19404390
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
17. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma.
Chao YC; Pan SH; Yang SC; Yu SL; Che TF; Lin CW; Tsai MS; Chang GC; Wu CH; Wu YY; Lee YC; Hong TM; Yang PC
Am J Respir Crit Care Med; 2009 Jan; 179(2):123-33. PubMed ID: 18787218
[TBL] [Abstract][Full Text] [Related]
18. Alpha-smooth muscle actin (ACTA2) is required for metastatic potential of human lung adenocarcinoma.
Lee HW; Park YM; Lee SJ; Cho HJ; Kim DH; Lee JI; Kang MS; Seol HJ; Shim YM; Nam DH; Kim HH; Joo KM
Clin Cancer Res; 2013 Nov; 19(21):5879-89. PubMed ID: 23995859
[TBL] [Abstract][Full Text] [Related]
19. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
20. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
